Table 1.
Multivariate prognostic impact of histone deacetylase expression in gynecologic entities.
| Gynecologic entity | Isoform | HR | 95% CI | p-value | End point | Material | Ref. |
|---|---|---|---|---|---|---|---|
| Endometrial endometrioid carcinoma (n = 123) |
HDAC1 | 2.19 | 0.71–6.83 | 0.18 | DSS | Protein | [44] |
| HDAC2 | 1.14 | 0.25–5.10 | 0.87 | DSS | Protein | ||
| HDAC3 | 1.53 | 0.35–6.80 | 0.58 | DSS | Protein | ||
| Ovarian serous carcinoma (n = 176) |
HDAC1 | 0.93 | 0.59–1.48 | 0.81 | DFS | Protein | [44] |
| HDAC2 | 1.00 | 0.05–20.00 | 0.02 | DFS | Protein | ||
| HDAC3 | 1.07 | 0.46–2.47 | 0.09 | DFS | Protein | ||
| Ovarian endometrioid carcinoma (n = 114) |
HDAC1 | 6.10 | 1.69–21.98 | <0.01 | DSS | Protein | [44] |
| HDAC2 | 1.20 | 0.14–10.47 | 0.87 | DSS | Protein | ||
| HDAC3 | 4.13 | 0.64–26.85 | 0.14 | DSS | Protein |
Data were calculated on the basis of the cohorts given in the respective references. HRs are given for high isoform expression; to match this, data from references were partially transformed. p-values < 0.05 were considered significant.
DFS: Disease-free survival; DSS: Disease-specific survival; HDAC: Histone deacetylase; HR: Hazard ratio.